Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer
Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer
复制标题
60 岁或以上雌激素受体阳性、HER2 阴性浸润性乳腺癌女性新辅助内分泌治疗的最佳治疗持续时间
DOI：
10.1272/jnms.jnms.2021_88-509
复制
发表时间：
2021
影响因子：
1
通讯作者：
Saitama Breast Cancer Clinical Study Group (SBCCSG)
中科院分区：
文献类型：
--
作者：
Hayashi Yuji;Takei Hiroyuki;Saito Tsuyoshi;Kai Toshihiro;Inoue Kenichi;Kurosumi Masafumi;Ninomiya Jun;Saitama Breast Cancer Clinical Study Group (SBCCSG)
